Werewolf Therapeutics Inc
HOWL
$6.21
Closing
▼-2.82%
1D
▲60.88%
YTD
Market cap
$269.19M
52 week high
$8.11
52 week low
$1.68
Volume
27,868
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$269.19M
Analysts' Rating
STRONG BUY
Price Target (Mean)
12.8
Total Analysts
5
P/E
Operating Margin
-156.88%
Beta
Revenue Growth (Annual)
0.00%
52 week high
$8.11
52 week low
$1.68
Div. Yield
%
EPS Annual Growth
64.29
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Werewolf Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The Company is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the objective of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to activate selectively in the tumor microenvironment. Its clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules, respectively, for the treatment of solid tumors. It is focused on advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. Its pipeline also includes JZP898 and WTX-712.
